JP2005526765A - Ｃｄｋ−阻害性２−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用 - Google Patents

Ｃｄｋ−阻害性２−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用 Download PDF

Info

Publication number: JP2005526765A
Authority: JP; Japan
Prior art keywords: alkyl; hydroxy; alkoxy; cycloalkyl; halogen
Prior art date: 2002-03-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2003574654A

Other languages

English (en)

Japanese (ja)

Inventor

リュッキンク，ウルリッヒ

クリューガー，マルティン

ヤウテラト，ロルフ

プリエン，オラフ

ジーマイスター，ゲルト

エルンスト，アレクサンダー

Original Assignee

シエーリングアクチエンゲゼルシャフト

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-11

Filing date

2003-02-26

Publication date

2005-09-08

2002-03-11 Priority claimed from DE2002112100 external-priority patent/DE10212100A1/de

2002-11-26 Priority claimed from DE10255984A external-priority patent/DE10255984A1/de

2003-02-26 Application filed by シエーリングアクチエンゲゼルシャフト filed Critical シエーリングアクチエンゲゼルシャフト

2005-09-08 Publication of JP2005526765A publication Critical patent/JP2005526765A/ja

Status Pending legal-status Critical Current

Links

238000004519 manufacturing process Methods 0.000 title claims abstract description 16
239000003814 drug Substances 0.000 title abstract description 3
230000002401 inhibitory effect Effects 0.000 title description 4
108091007914 CDKs Proteins 0.000 claims abstract description 25
102000003903 Cyclin-dependent kinases Human genes 0.000 claims abstract description 11
108090000266 Cyclin-dependent kinases Proteins 0.000 claims abstract description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
201000010099 disease Diseases 0.000 claims abstract description 10
239000003112 inhibitor Substances 0.000 claims abstract description 8
229910052736 halogen Inorganic materials 0.000 claims description 157
150000002367 halogens Chemical class 0.000 claims description 157
-1 C 1 -C 6 -alkoxy Chemical group 0.000 claims description 93
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 81
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 78
229910052739 hydrogen Inorganic materials 0.000 claims description 75
239000001257 hydrogen Substances 0.000 claims description 73
150000002431 hydrogen Chemical class 0.000 claims description 63
150000001875 compounds Chemical class 0.000 claims description 62
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 58
229910052760 oxygen Inorganic materials 0.000 claims description 58
239000001301 oxygen Substances 0.000 claims description 58
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 50
229910052757 nitrogen Inorganic materials 0.000 claims description 40
229910052717 sulfur Inorganic materials 0.000 claims description 40
125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 38
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 38
239000011593 sulfur Substances 0.000 claims description 38
125000005842 heteroatom Chemical group 0.000 claims description 33
125000001072 heteroaryl group Chemical group 0.000 claims description 32
125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 30
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 28
125000003118 aryl group Chemical group 0.000 claims description 28
125000004093 cyano group Chemical group *C#N 0.000 claims description 28
150000003839 salts Chemical class 0.000 claims description 27
125000005865 C2-C10alkynyl group Chemical group 0.000 claims description 24
125000004434 sulfur atom Chemical group 0.000 claims description 22
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 21
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 20
125000005843 halogen group Chemical group 0.000 claims description 19
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 18
229910052799 carbon Inorganic materials 0.000 claims description 18
206010028980 Neoplasm Diseases 0.000 claims description 16
239000000460 chlorine Substances 0.000 claims description 16
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims description 15
102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims description 15
229910052801 chlorine Inorganic materials 0.000 claims description 14
230000004770 neurodegeneration Effects 0.000 claims description 14
208000015122 neurodegenerative disease Diseases 0.000 claims description 14
125000003545 alkoxy group Chemical group 0.000 claims description 13
125000000217 alkyl group Chemical group 0.000 claims description 13
125000006728 (C1-C6) alkynyl group Chemical group 0.000 claims description 12
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 12
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 11
102100032857 Cyclin-dependent kinase 1 Human genes 0.000 claims description 10
101710106279 Cyclin-dependent kinase 1 Proteins 0.000 claims description 10
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
201000011510 cancer Diseases 0.000 claims description 10
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 9
201000004384 Alopecia Diseases 0.000 claims description 8
208000023275 Autoimmune disease Diseases 0.000 claims description 8
208000024172 Cardiovascular disease Diseases 0.000 claims description 8
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 8
231100000360 alopecia Toxicity 0.000 claims description 8
208000015181 infectious disease Diseases 0.000 claims description 8
208000017169 kidney disease Diseases 0.000 claims description 8
239000008177 pharmaceutical agent Substances 0.000 claims description 8
208000035473 Communicable disease Diseases 0.000 claims description 7
208000036142 Viral infection Diseases 0.000 claims description 7
230000001154 acute effect Effects 0.000 claims description 7
230000001684 chronic effect Effects 0.000 claims description 7
239000013067 intermediate product Substances 0.000 claims description 7
230000009385 viral infection Effects 0.000 claims description 7
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 6
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
239000000126 substance Substances 0.000 claims description 6
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
229910052794 bromium Inorganic materials 0.000 claims description 5
208000030507 AIDS Diseases 0.000 claims description 4
208000024827 Alzheimer disease Diseases 0.000 claims description 4
206010003210 Arteriosclerosis Diseases 0.000 claims description 4
201000006474 Brain Ischemia Diseases 0.000 claims description 4
108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 4
102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims description 4
206010012289 Dementia Diseases 0.000 claims description 4
206010018364 Glomerulonephritis Diseases 0.000 claims description 4
208000031886 HIV Infections Diseases 0.000 claims description 4
208000023105 Huntington disease Diseases 0.000 claims description 4
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 4
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
208000018737 Parkinson disease Diseases 0.000 claims description 4
208000031481 Pathologic Constriction Diseases 0.000 claims description 4
108091000080 Phosphotransferase Proteins 0.000 claims description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
201000004681 Psoriasis Diseases 0.000 claims description 4
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 4
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
239000002246 antineoplastic agent Substances 0.000 claims description 4
208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
229940127089 cytotoxic agent Drugs 0.000 claims description 4
230000005764 inhibitory process Effects 0.000 claims description 4
208000032839 leukemia Diseases 0.000 claims description 4
210000003097 mucus Anatomy 0.000 claims description 4
201000006417 multiple sclerosis Diseases 0.000 claims description 4
244000045947 parasite Species 0.000 claims description 4
102000020233 phosphotransferase Human genes 0.000 claims description 4
208000037803 restenosis Diseases 0.000 claims description 4
230000028327 secretion Effects 0.000 claims description 4
230000036262 stenosis Effects 0.000 claims description 4
208000037804 stenosis Diseases 0.000 claims description 4
206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 claims description 3
108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims description 3
102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims description 3
102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 claims description 3
208000005176 Hepatitis C Diseases 0.000 claims description 3
206010008118 cerebral infarction Diseases 0.000 claims description 3
125000001309 chloro group Chemical group Cl* 0.000 claims description 3
229930192474 thiophene Chemical group 0.000 claims description 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical group C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 claims description 2
BRUWSFUBFQYNPG-UHFFFAOYSA-N 1-phenoxypiperidine Chemical compound C1CCCCN1OC1=CC=CC=C1 BRUWSFUBFQYNPG-UHFFFAOYSA-N 0.000 claims description 2
YTQQIHUQLOZOJI-UHFFFAOYSA-N 2,3-dihydro-1,2-thiazole Chemical compound C1NSC=C1 YTQQIHUQLOZOJI-UHFFFAOYSA-N 0.000 claims description 2
VPGIYLLXBOUILV-UHFFFAOYSA-N 2-benzylthiophene Chemical compound C=1C=CC=CC=1CC1=CC=CS1 VPGIYLLXBOUILV-UHFFFAOYSA-N 0.000 claims description 2
102100036329 Cyclin-dependent kinase 3 Human genes 0.000 claims description 2
102100026810 Cyclin-dependent kinase 7 Human genes 0.000 claims description 2
102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims description 2
108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims description 2
101000715946 Homo sapiens Cyclin-dependent kinase 3 Proteins 0.000 claims description 2
101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 claims description 2
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 2
208000002672 hepatitis B Diseases 0.000 claims description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
239000000825 pharmaceutical preparation Substances 0.000 claims description 2
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 2
125000004356 hydroxy functional group Chemical group O* 0.000 claims 75
102100024456 Cyclin-dependent kinase 8 Human genes 0.000 claims 1
101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 claims 1
229910052740 iodine Inorganic materials 0.000 abstract description 3
229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract description 3
229940079593 drug Drugs 0.000 abstract description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 75
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 35
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 35
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
210000004027 cell Anatomy 0.000 description 30
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
239000000243 solution Substances 0.000 description 20
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
239000000047 product Substances 0.000 description 17
238000005160 1H NMR spectroscopy Methods 0.000 description 16
238000001704 evaporation Methods 0.000 description 16
230000008020 evaporation Effects 0.000 description 16
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
230000022131 cell cycle Effects 0.000 description 15
239000000203 mixture Substances 0.000 description 14
230000015572 biosynthetic process Effects 0.000 description 13
239000011541 reaction mixture Substances 0.000 description 13
238000006366 phosphorylation reaction Methods 0.000 description 11
230000000694 effects Effects 0.000 description 10
230000026731 phosphorylation Effects 0.000 description 10
238000010992 reflux Methods 0.000 description 10
238000004587 chromatography analysis Methods 0.000 description 9
238000001816 cooling Methods 0.000 description 9
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
230000001105 regulatory effect Effects 0.000 description 8
238000003756 stirring Methods 0.000 description 8
JDYQZLNQRKFDKE-UHFFFAOYSA-N 4-aminothiophene-2-sulfonamide Chemical compound NC1=CSC(S(N)(=O)=O)=C1 JDYQZLNQRKFDKE-UHFFFAOYSA-N 0.000 description 7
101100273648 Mus musculus Ccna2 gene Proteins 0.000 description 7
229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 7
230000035772 mutation Effects 0.000 description 7
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
102000016736 Cyclin Human genes 0.000 description 6
108050006400 Cyclin Proteins 0.000 description 6
101100327242 Drosophila melanogaster CycE gene Proteins 0.000 description 6
230000002779 inactivation Effects 0.000 description 6
239000002244 precipitate Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
210000004881 tumor cell Anatomy 0.000 description 6
AETJEQYXIRKFGW-UHFFFAOYSA-N 5-[(5-bromo-4-chloropyrimidin-2-yl)amino]pyridine-2-sulfonamide Chemical compound C1=NC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(Cl)=N1 AETJEQYXIRKFGW-UHFFFAOYSA-N 0.000 description 5
FCIKHUVSUVXRPU-UHFFFAOYSA-N 5-aminothiophene-2-sulfonamide Chemical compound NC1=CC=C(S(N)(=O)=O)S1 FCIKHUVSUVXRPU-UHFFFAOYSA-N 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
230000018199 S phase Effects 0.000 description 5
239000012043 crude product Substances 0.000 description 5
239000013078 crystal Substances 0.000 description 5
230000006870 function Effects 0.000 description 5
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
WUMGHGGPZKZYNN-UHFFFAOYSA-N 4-nitrothiophene-2-sulfonyl chloride Chemical compound [O-][N+](=O)C1=CSC(S(Cl)(=O)=O)=C1 WUMGHGGPZKZYNN-UHFFFAOYSA-N 0.000 description 4
QEEBODDKEOIYLQ-UHFFFAOYSA-N 5-nitrothiophene-2-sulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)S1 QEEBODDKEOIYLQ-UHFFFAOYSA-N 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 4
101100112680 Ostreococcus tauri CycD gene Proteins 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 4
230000014509 gene expression Effects 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
239000012071 phase Substances 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
230000017854 proteolysis Effects 0.000 description 4
230000022983 regulation of cell cycle Effects 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000000758 substrate Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
TVZZBHGLYQFVFJ-AXDJPCEYSA-N (2r)-2-[[5-bromo-2-[(5-methylsulfinyl-1h-1,2,4-triazol-3-yl)amino]pyrimidin-4-yl]amino]-3-methylbutan-1-ol Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2NC(=NN=2)S(C)=O)=N1 TVZZBHGLYQFVFJ-AXDJPCEYSA-N 0.000 description 3
ZQRWDLMVHKMQTM-UHFFFAOYSA-N 4-(5-bromo-2-chloropyrimidin-4-yl)sulfanylbutan-1-ol Chemical compound OCCCCSC1=NC(Cl)=NC=C1Br ZQRWDLMVHKMQTM-UHFFFAOYSA-N 0.000 description 3
LGQOCYPENVDLLH-UHFFFAOYSA-N 4-aminothiophene-2-sulfonyl fluoride Chemical compound NC1=CSC(S(F)(=O)=O)=C1 LGQOCYPENVDLLH-UHFFFAOYSA-N 0.000 description 3
HJTNWXMYDPFJLI-UHFFFAOYSA-N 4-nitrothiophene-2-sulfonyl fluoride Chemical compound [O-][N+](=O)C1=CSC(S(F)(=O)=O)=C1 HJTNWXMYDPFJLI-UHFFFAOYSA-N 0.000 description 3
ZEPDMAOWHACSFU-UHFFFAOYSA-N 5-[(5-bromo-6-oxo-1h-pyrimidin-2-yl)amino]pyridine-2-sulfonamide Chemical compound C1=NC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(O)=N1 ZEPDMAOWHACSFU-UHFFFAOYSA-N 0.000 description 3
SFCUESWCLXDTCC-UHFFFAOYSA-N 5-aminopyridine-2-sulfonamide Chemical compound NC1=CC=C(S(N)(=O)=O)N=C1 SFCUESWCLXDTCC-UHFFFAOYSA-N 0.000 description 3
UFRBNQMXJQJRFT-UHFFFAOYSA-N 5-aminothiophene-2-sulfonyl fluoride Chemical compound NC1=CC=C(S(F)(=O)=O)S1 UFRBNQMXJQJRFT-UHFFFAOYSA-N 0.000 description 3
STYRWDYHCFWUMN-UHFFFAOYSA-N 5-nitrothiophene-2-sulfonyl fluoride Chemical compound [O-][N+](=O)C1=CC=C(S(F)(=O)=O)S1 STYRWDYHCFWUMN-UHFFFAOYSA-N 0.000 description 3
102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 3
230000005778 DNA damage Effects 0.000 description 3
231100000277 DNA damage Toxicity 0.000 description 3
230000004543 DNA replication Effects 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
230000010190 G1 phase Effects 0.000 description 3
238000005481 NMR spectroscopy Methods 0.000 description 3
108091023040 Transcription factor Proteins 0.000 description 3
102000040945 Transcription factor Human genes 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
102000007588 cdc25 Phosphatases Human genes 0.000 description 3
108010046616 cdc25 Phosphatases Proteins 0.000 description 3
230000025084 cell cycle arrest Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
230000011278 mitosis Effects 0.000 description 3
150000003230 pyrimidines Chemical class 0.000 description 3
150000003254 radicals Chemical class 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
SITYVVBVXXFFAL-ZETCQYMHSA-N (2r)-2-[(5-bromo-2-chloropyrimidin-4-yl)amino]-3-methylbutan-1-ol Chemical compound CC(C)[C@H](CO)NC1=NC(Cl)=NC=C1Br SITYVVBVXXFFAL-ZETCQYMHSA-N 0.000 description 2
HYRSGPDJPDMBRK-QMMMGPOBSA-N (2r)-2-[[5-bromo-2-[(3-methylsulfanyl-1h-1,2,4-triazol-5-yl)amino]pyrimidin-4-yl]amino]-3-methylbutan-1-ol Chemical compound N1C(SC)=NN=C1NC1=NC=C(Br)C(N[C@@H](CO)C(C)C)=N1 HYRSGPDJPDMBRK-QMMMGPOBSA-N 0.000 description 2
WXOYPSBPSIVQDF-QMMMGPOBSA-N (2r)-2-[[5-bromo-2-[(5-methylsulfonyl-1h-1,2,4-triazol-3-yl)amino]pyrimidin-4-yl]amino]-3-methylbutan-1-ol Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2NC(=NN=2)S(C)(=O)=O)=N1 WXOYPSBPSIVQDF-QMMMGPOBSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
SQWHKNROUNUVRH-SSDOTTSWSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]thiophene-2-sulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(SC=2)S(N)(=O)=O)=N1 SQWHKNROUNUVRH-SSDOTTSWSA-N 0.000 description 2
229960000549 4-dimethylaminophenol Drugs 0.000 description 2
MCFUYNDWFJAZPF-UHFFFAOYSA-N 5-[[5-bromo-4-(2-hydroxypentan-3-ylsulfanyl)pyrimidin-2-yl]amino]pyridine-2-sulfonamide Chemical compound C1=C(Br)C(SC(CC)C(C)O)=NC(NC=2C=NC(=CC=2)S(N)(=O)=O)=N1 MCFUYNDWFJAZPF-UHFFFAOYSA-N 0.000 description 2
RLTZXVJBMPNUFM-UHFFFAOYSA-N 5-[[5-bromo-4-(2-oxopentan-3-ylsulfanyl)pyrimidin-2-yl]amino]pyridine-2-sulfonamide Chemical compound C1=C(Br)C(SC(CC)C(C)=O)=NC(NC=2C=NC(=CC=2)S(N)(=O)=O)=N1 RLTZXVJBMPNUFM-UHFFFAOYSA-N 0.000 description 2
CUOLLDJNHVYWCZ-UHFFFAOYSA-N 5-[[5-bromo-4-(3-hydroxy-3-methylbutan-2-yl)sulfanylpyrimidin-2-yl]amino]pyridine-2-sulfonamide Chemical compound C1=C(Br)C(SC(C)C(C)(C)O)=NC(NC=2C=NC(=CC=2)S(N)(=O)=O)=N1 CUOLLDJNHVYWCZ-UHFFFAOYSA-N 0.000 description 2
WOMQYYJTGYKGBY-UHFFFAOYSA-N 5-[[5-bromo-4-(4-hydroxybutylsulfanyl)pyrimidin-2-yl]amino]pyridine-2-sulfonamide Chemical compound C1=NC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(SCCCCO)=N1 WOMQYYJTGYKGBY-UHFFFAOYSA-N 0.000 description 2
MSNMQZCVDZMYDU-UHFFFAOYSA-N 5-[[5-bromo-4-(cyclopropylmethylamino)pyrimidin-2-yl]amino]pyridine-2-sulfonamide Chemical compound C1=NC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCC2CC2)=N1 MSNMQZCVDZMYDU-UHFFFAOYSA-N 0.000 description 2
SNTOAMXUUNOKHQ-UHFFFAOYSA-N 5-[[5-bromo-4-[3-(cyclopropylamino)butan-2-ylamino]pyrimidin-2-yl]amino]pyridine-2-sulfonamide Chemical compound N=1C(NC=2C=NC(=CC=2)S(N)(=O)=O)=NC=C(Br)C=1NC(C)C(C)NC1CC1 SNTOAMXUUNOKHQ-UHFFFAOYSA-N 0.000 description 2
QYDMNTRYQIICPV-UHFFFAOYSA-N 5-[[5-bromo-4-[3-hydroxybutan-2-yl(methyl)amino]pyrimidin-2-yl]amino]pyridine-2-sulfonamide Chemical compound C1=C(Br)C(N(C)C(C)C(O)C)=NC(NC=2C=NC(=CC=2)S(N)(=O)=O)=N1 QYDMNTRYQIICPV-UHFFFAOYSA-N 0.000 description 2
SIKXIUWKPGWBBF-UHFFFAOYSA-N 5-bromo-2,4-dichloropyrimidine Chemical compound ClC1=NC=C(Br)C(Cl)=N1 SIKXIUWKPGWBBF-UHFFFAOYSA-N 0.000 description 2
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
230000010337 G2 phase Effects 0.000 description 2
102000003964 Histone deacetylase Human genes 0.000 description 2
108090000353 Histone deacetylase Proteins 0.000 description 2
108010033040 Histones Proteins 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
101100059444 Mus musculus Ccnb1 gene Proteins 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
239000007868 Raney catalyst Substances 0.000 description 2
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
229910000564 Raney nickel Inorganic materials 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
239000002585 base Substances 0.000 description 2
125000005605 benzo group Chemical group 0.000 description 2
OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000006369 cell cycle progression Effects 0.000 description 2
230000032823 cell division Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 2
GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
238000001035 drying Methods 0.000 description 2
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
108091006086 inhibitor proteins Proteins 0.000 description 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000002609 medium Substances 0.000 description 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
XGXNTJHZPBRBHJ-UHFFFAOYSA-N n-phenylpyrimidin-2-amine Chemical compound N=1C=CC=NC=1NC1=CC=CC=C1 XGXNTJHZPBRBHJ-UHFFFAOYSA-N 0.000 description 2
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
238000000746 purification Methods 0.000 description 2
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
239000007858 starting material Substances 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
CEIIUITVLQMXBT-RXMQYKEDSA-N (2r)-2-[(5-bromo-2-chloropyrimidin-4-yl)amino]butan-1-ol Chemical compound CC[C@H](CO)NC1=NC(Cl)=NC=C1Br CEIIUITVLQMXBT-RXMQYKEDSA-N 0.000 description 1
ISPUYSGFPPFZAX-SCSAIBSYSA-N (2r)-2-[(5-bromo-2-chloropyrimidin-4-yl)amino]propan-1-ol Chemical compound OC[C@@H](C)NC1=NC(Cl)=NC=C1Br ISPUYSGFPPFZAX-SCSAIBSYSA-N 0.000 description 1
CUGDYSSBTWBKII-LXGUWJNJSA-N (2r,3r,4r,5s)-6-(dimethylamino)hexane-1,2,3,4,5-pentol Chemical compound CN(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO CUGDYSSBTWBKII-LXGUWJNJSA-N 0.000 description 1
IKXCHOUDIPZROZ-LXGUWJNJSA-N (2r,3r,4r,5s)-6-(ethylamino)hexane-1,2,3,4,5-pentol Chemical compound CCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO IKXCHOUDIPZROZ-LXGUWJNJSA-N 0.000 description 1
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
239000001082 (3R)-3-sulfanylpentan-2-one Substances 0.000 description 1
125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
CRPTXKKKIGGDBX-UHFFFAOYSA-N (z)-but-2-ene Chemical group [CH2]C=CC CRPTXKKKIGGDBX-UHFFFAOYSA-N 0.000 description 1
0 **c1c(*)cnc(Nc2c[s]c(S(F)(=O)=O)c2)n1 Chemical compound **c1c(*)cnc(Nc2c[s]c(S(F)(=O)=O)c2)n1 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 1
ZGCHLAJIRWDGFE-UHFFFAOYSA-N 1-aminopropane-1,1-diol Chemical compound CCC(N)(O)O ZGCHLAJIRWDGFE-UHFFFAOYSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
NWYYWIJOWOLJNR-UHFFFAOYSA-N 2-Amino-3-methyl-1-butanol Chemical compound CC(C)C(N)CO NWYYWIJOWOLJNR-UHFFFAOYSA-N 0.000 description 1
KTFDYVNEGTXQCV-UHFFFAOYSA-N 2-Thiophenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CS1 KTFDYVNEGTXQCV-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical compound OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
SZECUQRKLXRGSJ-UHFFFAOYSA-N 3-Mercapto-2-pentanone Chemical compound CCC(S)C(C)=O SZECUQRKLXRGSJ-UHFFFAOYSA-N 0.000 description 1
OVKDLPZRDQTOJW-UHFFFAOYSA-N 3-amino-2-methylbutan-2-ol Chemical compound CC(N)C(C)(C)O OVKDLPZRDQTOJW-UHFFFAOYSA-N 0.000 description 1
SQWHKNROUNUVRH-UHFFFAOYSA-N 4-[[5-bromo-4-(1-hydroxybutan-2-ylamino)pyrimidin-2-yl]amino]thiophene-2-sulfonamide Chemical compound C1=C(Br)C(NC(CO)CC)=NC(NC=2C=C(SC=2)S(N)(=O)=O)=N1 SQWHKNROUNUVRH-UHFFFAOYSA-N 0.000 description 1
OWTIPOVOAZFVAF-UHFFFAOYSA-N 4-[[5-bromo-4-(1-hydroxypropan-2-ylamino)pyrimidin-2-yl]amino]-n-(cyclopropylmethyl)thiophene-2-sulfonamide Chemical compound C1=C(Br)C(NC(CO)C)=NC(NC=2C=C(SC=2)S(=O)(=O)NCC2CC2)=N1 OWTIPOVOAZFVAF-UHFFFAOYSA-N 0.000 description 1
FCEWDSWCOMLHCM-UHFFFAOYSA-N 4-[[5-bromo-4-(1-hydroxypropan-2-ylamino)pyrimidin-2-yl]amino]thiophene-2-sulfonyl fluoride Chemical compound C1=C(Br)C(NC(CO)C)=NC(NC=2C=C(SC=2)S(F)(=O)=O)=N1 FCEWDSWCOMLHCM-UHFFFAOYSA-N 0.000 description 1
OWTIPOVOAZFVAF-SECBINFHSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(cyclopropylmethyl)thiophene-2-sulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(SC=2)S(=O)(=O)NCC2CC2)=N1 OWTIPOVOAZFVAF-SECBINFHSA-N 0.000 description 1
FCEWDSWCOMLHCM-ZCFIWIBFSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]thiophene-2-sulfonyl fluoride Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(SC=2)S(F)(=O)=O)=N1 FCEWDSWCOMLHCM-ZCFIWIBFSA-N 0.000 description 1
WIFPJDJJFUSIFP-UHFFFAOYSA-N 4-aminobutane-1,2,3-triol Chemical compound NCC(O)C(O)CO WIFPJDJJFUSIFP-UHFFFAOYSA-N 0.000 description 1
FGDGJJNJEUYMFK-UHFFFAOYSA-N 4-n,6-n-diphenylpyrimidine-4,6-diamine Chemical class C=1C(NC=2C=CC=CC=2)=NC=NC=1NC1=CC=CC=C1 FGDGJJNJEUYMFK-UHFFFAOYSA-N 0.000 description 1
NEJMTSWXTZREOC-UHFFFAOYSA-N 4-sulfanylbutan-1-ol Chemical compound OCCCCS NEJMTSWXTZREOC-UHFFFAOYSA-N 0.000 description 1
HFAXITWIPFQCQM-UHFFFAOYSA-N 5-[[5-bromo-4-(3-hydroxybutan-2-yloxy)pyrimidin-2-yl]amino]pyridine-2-sulfonamide Chemical compound C1=C(Br)C(OC(C)C(O)C)=NC(NC=2C=NC(=CC=2)S(N)(=O)=O)=N1 HFAXITWIPFQCQM-UHFFFAOYSA-N 0.000 description 1
HXHDKZHSAIYERC-UHFFFAOYSA-N 5-[[5-bromo-4-(3-oxobutan-2-ylamino)pyrimidin-2-yl]amino]pyridine-2-sulfonamide Chemical compound C1=C(Br)C(NC(C)C(C)=O)=NC(NC=2C=NC(=CC=2)S(N)(=O)=O)=N1 HXHDKZHSAIYERC-UHFFFAOYSA-N 0.000 description 1
PADWTIJVQSNICR-MRVPVSSYSA-N 5-[[5-bromo-4-[[(2r)-3-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]pyridine-2-sulfonamide Chemical compound C1=C(Br)C(N[C@H](C)C(C)(C)O)=NC(NC=2C=NC(=CC=2)S(N)(=O)=O)=N1 PADWTIJVQSNICR-MRVPVSSYSA-N 0.000 description 1
GIRDZQOHBHZJCC-UHFFFAOYSA-N 5-bromo-2-chloro-1h-pyrimidin-6-one Chemical compound ClC1=NC=C(Br)C(=O)N1 GIRDZQOHBHZJCC-UHFFFAOYSA-N 0.000 description 1
QCOPMXKXQGLHML-UHFFFAOYSA-N 5-bromo-2-chloro-n-(cyclopropylmethyl)pyrimidin-4-amine Chemical compound ClC1=NC=C(Br)C(NCC2CC2)=N1 QCOPMXKXQGLHML-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
102100036464 Activated RNA polymerase II transcriptional coactivator p15 Human genes 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
YESJXSLUUKZSFP-HTQZYQBOSA-O C[C@H]([C@@H](C)Oc(nc(Nc(cn1)ccc1[SH+]N)nc1)c1Br)O Chemical compound C[C@H]([C@@H](C)Oc(nc(Nc(cn1)ccc1[SH+]N)nc1)c1Br)O YESJXSLUUKZSFP-HTQZYQBOSA-O 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
102000006459 Checkpoint Kinase 1 Human genes 0.000 description 1
108010019244 Checkpoint Kinase 1 Proteins 0.000 description 1
102000008169 Co-Repressor Proteins Human genes 0.000 description 1
108010025461 Cyclin-Dependent Kinase 9 Proteins 0.000 description 1
102000013702 Cyclin-Dependent Kinase 9 Human genes 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
108010093502 E2F Transcription Factors Proteins 0.000 description 1
102000001388 E2F Transcription Factors Human genes 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108091007911 GSKs Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000034951 Genetic Translocation Diseases 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
102000004103 Glycogen Synthase Kinases Human genes 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
102100025169 Max-binding protein MNT Human genes 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
101150092630 Myt1 gene Proteins 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
241000224016 Plasmodium Species 0.000 description 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
102100022151 Ragulator complex protein LAMTOR1 Human genes 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
108050002653 Retinoblastoma protein Proteins 0.000 description 1
108010077895 Sarcosine Proteins 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
108700025695 Suppressor Genes Proteins 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
241000223996 Toxoplasma Species 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
241000223104 Trypanosoma Species 0.000 description 1
108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
102400000757 Ubiquitin Human genes 0.000 description 1
108090000848 Ubiquitin Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
101150040313 Wee1 gene Proteins 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
101150073031 cdk2 gene Proteins 0.000 description 1
230000009743 cell cycle entry Effects 0.000 description 1
230000006727 cell loss Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000013000 chemical inhibitor Substances 0.000 description 1
150000001805 chlorine compounds Chemical group 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000026374 cyclin catabolic process Effects 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000030609 dephosphorylation Effects 0.000 description 1
238000006209 dephosphorylation reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229940031098 ethanolamine Drugs 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
239000000417 fungicide Substances 0.000 description 1
230000005251 gamma ray Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
150000002366 halogen compounds Chemical group 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000002390 heteroarenes Chemical class 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000003463 hyperproliferative effect Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
239000011630 iodine Substances 0.000 description 1
230000005865 ionizing radiation Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
238000000021 kinase assay Methods 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000010606 normalization Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
GTVPOLSIJWJJNY-UHFFFAOYSA-N olomoucine Chemical compound N1=C(NCCO)N=C2N(C)C=NC2=C1NCC1=CC=CC=C1 GTVPOLSIJWJJNY-UHFFFAOYSA-N 0.000 description 1
238000011017 operating method Methods 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
108700042657 p16 Genes Proteins 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
235000003270 potassium fluoride Nutrition 0.000 description 1
239000011698 potassium fluoride Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000012746 preparative thin layer chromatography Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
XVIAPHVAGFEFFN-UHFFFAOYSA-N pyrimidine-5-carbonitrile Chemical compound N#CC1=CN=CN=C1 XVIAPHVAGFEFFN-UHFFFAOYSA-N 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000009711 regulatory function Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000028617 response to DNA damage stimulus Effects 0.000 description 1
229940043230 sarcosine Drugs 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
230000008685 targeting Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
VNNLHYZDXIBHKZ-UHFFFAOYSA-N thiophene-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CS1 VNNLHYZDXIBHKZ-UHFFFAOYSA-N 0.000 description 1
108091006105 transcriptional corepressors Proteins 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
108091006107 transcriptional repressors Proteins 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000014723 transformation of host cell by virus Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Immunology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Dermatology (AREA)
Transplantation (AREA)
Hematology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

JP2003574654A 2002-03-11 2003-02-26 Ｃｄｋ−阻害性２−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用 Pending JP2005526765A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE2002112100 DE10212100A1 (de)	2002-03-11	2002-03-11	CDK inhibitorische 2-Heteroaryl-Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE10255984A DE10255984A1 (de)	2002-11-26	2002-11-26	CDK inhibitorische 2-Heteroaryl-Pyrimidine, deren Herstellung und Verwendung als Arnzeimittel
PCT/EP2003/001995 WO2003076437A1 (fr)	2002-03-11	2003-02-26	2-heteroaryle-pyrimidines inhibitrices de la kinase dependante des cyclines, leur production et leur utilisation comme medicaments

Publications (1)

Publication Number	Publication Date
JP2005526765A true JP2005526765A (ja)	2005-09-08

Family

ID=27806091

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2003574654A Pending JP2005526765A (ja)	2002-03-11	2003-02-26	Ｃｄｋ−阻害性２−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用

Country Status (8)

Country	Link
EP (1)	EP1483260A1 (fr)
JP (1)	JP2005526765A (fr)
AR (1)	AR038922A1 (fr)
AU (1)	AU2003212282A1 (fr)
PE (1)	PE20040156A1 (fr)
TW (1)	TW200406406A (fr)
UY (1)	UY27714A1 (fr)
WO (1)	WO2003076437A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2010516788A (ja) *	2007-01-31	2010-05-20	サイトピア・リサーチ・ピーティーワイ・リミテッド	チオピリミジンベースの化合物およびその使用
JP2011513230A (ja) *	2008-02-22	2011-04-28	ライジェルファーマシューティカルズ，インコーポレイテッド	アテローム性動脈硬化症の治療のための２，４−ピリミジンジアミンの使用
JP2013545741A (ja) *	2010-11-10	2013-12-26	エフ．ホフマン−ラロシュアーゲー	Ｌｒｒｋ２調節薬としてのピラゾールアミノピリミジン誘導体
JP2021522349A (ja) *	2018-05-04	2021-08-30	インフレイゾームリミテッド	新規な化合物
JP2024506116A (ja) *	2020-11-27	2024-02-09	オールオリオンセラピューティクスインコーポレイテッド	アミノヘテロアリールキナーゼ阻害剤

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
IL166241A0 (en)	2002-07-29	2006-01-15	Rigel Pharmaceuticals Inc	Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
RS53109B (sr)	2003-07-30	2014-06-30	Rigel Pharmaceuticals Inc.	Jedinjenja 2,4 pirimidindiamina za upotrebu u tretmanu ili prevenciji autoimunih bolesti
DE10349423A1 (de) *	2003-10-16	2005-06-16	Schering Ag	Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
WO2006034872A1 (fr) *	2004-09-29	2006-04-06	Bayer Schering Pharma Aktiengesellschaft	2-anilinopyrimidine substituee utilisee en tant que kinase a cycle cellulaire ou recepteur de la tyrosine kinase, leur production et leur utilisation en tant que medicament
ES2380550T3 (es)	2004-11-24	2012-05-16	Rigel Pharmaceuticals, Inc.	Compuestos de espiro-2,4-pirimidindiamina y sus usos
NZ555947A (en)	2005-01-19	2010-11-26	Rigel Pharmaceuticals Inc	Prodrugs of 2,4-pyrimidinediamine compounds and their uses
EP1710246A1 (fr) *	2005-04-08	2006-10-11	Schering Aktiengesellschaft	Macrocycles de sulfoximine-pyrmidine et leurs sels correspondants, leurs procédé de fabrication, et leurs utilisation pharmaceutique contre le cancer
MX286273B (es)	2005-06-08	2011-05-04	Rigel Pharmaceuticals Inc	Composiciones y metodos para inhibicion de la via jak.
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
EP2258359A3 (fr)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
US7678363B2 (en)	2005-08-26	2010-03-16	Braincells Inc	Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
WO2007047978A2 (fr)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation de la neurogenese par inhibition de la pde
AU2006308889A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	GABA receptor mediated modulation of neurogenesis
EP1803723A1 (fr)	2006-01-03	2007-07-04	Bayer Schering Pharma Aktiengesellschaft	Dérivés (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximide en tant qu'inhibiteurs de la kinase aurora pour le traitement de cancer
TW200736195A (en)	2006-02-17	2007-10-01	Wyeth Corp	Methods for preparing sulfonamide substituted alcohols and intermediates thereof
RU2008131051A (ru)	2006-02-17	2010-03-27	Вайет (Us)	Избирательное n-сульфонилирование 2-амино трифторалкильнзамещенных спиртов
CA2642229C (fr)	2006-02-24	2015-05-12	Rigel Pharmaceuticals, Inc.	Compositions et methodes destinees a l'inhibition de la voie jak
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
CA2651813A1 (fr)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenese par modulation de l'angiotensine
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
DE102007010801A1 (de)	2007-03-02	2008-09-04	Bayer Cropscience Ag	Diaminopyrimidine als Fungizide
CN101970417A (zh) *	2008-03-14	2011-02-09	巴斯夫欧洲公司	作为杀真菌剂使用的取代的吡嗪基甲基磺酰胺
CN102203086A (zh)	2008-09-03	2011-09-28	拜尔农作物科学股份公司	作为杀真菌剂的噻吩基氨基嘧啶类化合物
EP2179992A1 (fr)	2008-10-21	2010-04-28	Bayer Schering Pharma Aktiengesellschaft	Dérivés d'anilino-pyrimidine substitués par sulfone en tant qu'inhibiteurs de CDK, leur fabrication et leur utilisation en tant que médicaments
EP2179991A1 (fr) *	2008-10-21	2010-04-28	Bayer Schering Pharma Aktiengesellschaft	Dérivés d'anilino-pyrimidine substitués par sulfoximine en tant qu'inhibiteurs de CDK, leur fabrication et leur utilisation en tant que médicaments
EP2179993A1 (fr)	2008-10-21	2010-04-28	Bayer Schering Pharma Aktiengesellschaft	Dérivés d'anilino-pyrimidine substitués par sulfoxide en tant qu'inhibiteurs de CDK, leur fabrication et leur utilisation en tant que médicaments
WO2010099217A1 (fr)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
DE102009001438A1 (de)	2009-03-10	2010-09-16	Bayer Schering Pharma Aktiengesellschaft	Carbonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102009015070A1 (de)	2009-03-30	2010-10-14	Bayer Schering Pharma Aktiengesellschaft	Aminocabonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US8466155B2 (en) *	2009-10-02	2013-06-18	Boehringer Ingelheim International Gmbh	Pyrimidines
DE102010014427A1 (de)	2010-04-01	2011-10-06	Bayer Schering Pharma Aktiengesellschaft	Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010014426A1 (de)	2010-04-01	2011-10-06	Bayer Schering Pharma Aktiengesellschaft	Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
EP2827871A1 (fr)	2012-03-21	2015-01-28	Bayer Intellectual Property GmbH	Utilisation de (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-méthylpropyl]oxy}-5-(trifluorméthyl)pyrimidin-2-yl]amino}phényl)sulfoximide pour traiter des tumeurs spécifiques
HK1215256A1 (zh)	2012-11-20	2016-08-19	Vertex Pharmaceuticals Incorporated	用作吲哚胺2，3-二氧化酶的抑制劑的化合物
WO2014173815A1 (fr)	2013-04-23	2014-10-30	Bayer Pharma Aktiengesellschaft	Utilisation de (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-méthylpropyl]oxy}-5-(trifluorométhyl)pyrimidin-2-yl]amino}phényl)sulfoximide dans le traitement de tumeurs spécifiques
WO2019157020A1 (fr)	2018-02-06	2019-08-15	The Board Of Trustees Of The University Of Illinois	Analogues de benzothiophène substitués en tant qu'agents de dégradation sélectifs du récepteur d'œstrogènes
US11066404B2 (en)	2018-10-11	2021-07-20	Incyte Corporation	Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (fr)	2019-02-15	2020-08-20	Incyte Corporation	Composés de pyrrolo[2,3-d]pyrimidinone en tant qu'inhibiteurs de cdk2
TW202100520A (zh)	2019-03-05	2021-01-01	美商英塞特公司	作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11919904B2 (en)	2019-03-29	2024-03-05	Incyte Corporation	Sulfonylamide compounds as CDK2 inhibitors
EP3947368B1 (fr) *	2019-04-04	2025-09-03	Dana-Farber Cancer Institute, Inc.	Composés bifonctionells comprennant un ligand cdk2/5, un lieur et un dégron qui s'attache a la ligase d'ubiquitin e3 pour le traitement du cancer
US11447494B2 (en)	2019-05-01	2022-09-20	Incyte Corporation	Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en)	2019-05-01	2022-09-13	Incyte Corporation	Tricyclic amine compounds as CDK2 inhibitors
PH12022550361A1 (en)	2019-08-14	2023-02-27	Incyte Corp	Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
JP7693656B2 (ja)	2019-10-11	2025-06-17	インサイト・コーポレイション	Ｃｄｋ２阻害剤としての二環式アミン
US11981671B2 (en)	2021-06-21	2024-05-14	Incyte Corporation	Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en)	2021-12-10	2024-05-07	Incyte Corporation	Bicyclic amines as CDK2 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9828511D0 (en) *	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
GB0004888D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0016877D0 (en) *	2000-07-11	2000-08-30	Astrazeneca Ab	Chemical compounds

2003
- 2003-02-26 JP JP2003574654A patent/JP2005526765A/ja active Pending
- 2003-02-26 AU AU2003212282A patent/AU2003212282A1/en not_active Abandoned
- 2003-02-26 WO PCT/EP2003/001995 patent/WO2003076437A1/fr not_active Ceased
- 2003-02-26 EP EP03708151A patent/EP1483260A1/fr not_active Withdrawn
- 2003-03-10 PE PE2003000240A patent/PE20040156A1/es not_active Application Discontinuation
- 2003-03-11 TW TW092105221A patent/TW200406406A/zh unknown
- 2003-03-11 UY UY27714A patent/UY27714A1/es not_active Application Discontinuation
- 2003-03-11 AR ARP030100819A patent/AR038922A1/es unknown

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2010516788A (ja) *	2007-01-31	2010-05-20	サイトピア・リサーチ・ピーティーワイ・リミテッド	チオピリミジンベースの化合物およびその使用
JP2011513230A (ja) *	2008-02-22	2011-04-28	ライジェルファーマシューティカルズ，インコーポレイテッド	アテローム性動脈硬化症の治療のための２，４−ピリミジンジアミンの使用
JP2013545741A (ja) *	2010-11-10	2013-12-26	エフ．ホフマン−ラロシュアーゲー	Ｌｒｒｋ２調節薬としてのピラゾールアミノピリミジン誘導体
JP2018109038A (ja) *	2010-11-10	2018-07-12	ジェネンテック，インコーポレイテッド	Ｌｒｒｋ２調節薬としてのピラゾールアミノピリミジン誘導体
JP2021522349A (ja) *	2018-05-04	2021-08-30	インフレイゾームリミテッド	新規な化合物
JP2024506116A (ja) *	2020-11-27	2024-02-09	オールオリオンセラピューティクスインコーポレイテッド	アミノヘテロアリールキナーゼ阻害剤

Also Published As

Publication number	Publication date
WO2003076437A1 (fr)	2003-09-18
UY27714A1 (es)	2003-10-31
PE20040156A1 (es)	2004-06-07
EP1483260A1 (fr)	2004-12-08
AR038922A1 (es)	2005-02-02
AU2003212282A1 (en)	2003-09-22
TW200406406A (en)	2004-05-01

Publication	Publication Date	Title
JP2005526765A (ja)	2005-09-08	Ｃｄｋ−阻害性２−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用
US7288547B2 (en)	2007-10-30	CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
JP5344564B2 (ja)	2013-11-20	スルホキシイミン置換ピリミジン、それらの調製及び医薬としての使用
US7291624B2 (en)	2007-11-06	CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents
US6747046B2 (en)	2004-06-08	Substituted N-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl) derivatives, their production and use as pharmaceutical agents
ES2231725T3 (es)	2005-05-16	3,5-diamino-1,2,4-triazoles como agentes inhibidores de cinasas.
JP4700006B2 (ja)	2011-06-15	Ｃｄｋ−及び／又はｖｅｇｆインヒビターとしてのスルホキシミン−置換ピリミジン類、それらの生成及び医薬としての使用
US20020132792A1 (en)	2002-09-19	Aryl-substituted indirubin derivatives, their production and use
KR20050058360A (ko)	2005-06-16	마크로시클릭 피리미딘, 이의 제조 및 이의 약제로서의 사용
US20060111378A1 (en)	2006-05-25	Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents
US20020107404A1 (en)	2002-08-08	Sulfur-containing indirubin derivatives, their production and use
JP2004519502A (ja)	2004-07-02	高められた溶解性を有するｃｄｋ−阻害インジルビン誘導体
EP1705177A1 (fr)	2006-09-27	Pyrimidines substituées par une N-aryl-sulfoximine comme inhibiteurs de CDK et de VEGF, leur préparation et utilisation comme médicaments
JP2008538755A (ja)	2008-11-06	塩基性窒素を有さない新規チアゾリジノン類、それらの生成及び医薬剤としての使用
DE10127581A1 (de)	2003-01-02	CDK inhibitorische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE10212100A1 (de)	2003-10-23	CDK inhibitorische 2-Heteroaryl-Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE10255984A1 (de)	2004-08-12	CDK inhibitorische 2-Heteroaryl-Pyrimidine, deren Herstellung und Verwendung als Arnzeimittel

Legal Events

Date	Code	Title	Description
2006-02-28	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060227
2009-08-05	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090804
2010-01-06	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100105

Date

Code

Title

Description

2006-02-28

A621

Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060227

2009-08-05

A131

Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090804

2010-01-06

A02

Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100105